Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Special Issue: Recent Advances in Microglia Research.

International journal of molecular sciences·2025

Same author

Astrocytes phenomics as new druggable targets in healthy aging and Alzheimer's disease progression.

Frontiers in cellular neuroscience·2025

Same author

Prolonged incubation with Δ<sup>9</sup>-tetrahydrocannabinol but not with cannabidiol induces synaptic alterations and mitochondrial impairment in immature and mature rat organotypic hippocampal slices.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025

Same author

Chronic administration of prebiotics and probiotics ameliorates pathophysiological hallmarks of Alzheimer's disease in a APP/PS1 transgenic mouse model.

Frontiers in pharmacology·2024

Same author

Editorial: The role of the microbiota-gut-brain axis in the pathogenesis of neurodegenerative diseases.

Frontiers in neuroscience·2024

Same author

Morphofunctional Investigation in a Transgenic Mouse Model of Alzheimer's Disease: Non-Reactive Astrocytes Are Involved in Aβ Load and Reactive Astrocytes in Plaque Build-Up.

Cells·2023

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Cholinergic Ligand–dependent Modulation of Oxidative Phosphorylation Coupling in Digitonin-permeabilized BE(2)-C Neuroblastoma Cells

Cholinergic Ligand–dependent Modulation of Oxidative Phosphorylation Coupling in Digitonin-permeabilized BE(2)-C Neuroblastoma Cells

Published on: April 28, 2026

Cholinesterase inhibitors and beyond.

Giancarlo Pepeu¹, Maria Grazia Giovannini

¹Department of Preclinical and Clinical Pharmacology, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy. giancarlo.pepeu@unifi.it

Current Alzheimer Research

|April 10, 2009

Summary

Cholinesterase inhibitors (ChEIs) offer potential for Alzheimer Disease (AD) therapy, but clinical effectiveness remains debated. Future research focuses on novel multifunctional ChEIs for AD and other cognitive conditions.

More Related Videos

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

Related Experiment Videos

Last Updated: Jun 24, 2026

Cholinergic Ligand–dependent Modulation of Oxidative Phosphorylation Coupling in Digitonin-permeabilized BE(2)-C Neuroblastoma Cells

Cholinergic Ligand–dependent Modulation of Oxidative Phosphorylation Coupling in Digitonin-permeabilized BE(2)-C Neuroblastoma Cells

Published on: April 28, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

Area of Science:

Neuroscience
Pharmacology

Background:

Cholinesterase inhibitors (ChEIs) emerged in the 1990s for Alzheimer Disease (AD) therapy, generating significant research interest.
Animal models consistently show ChEIs increase brain acetylcholine and improve cognitive deficits in AD.
Despite extensive research, clinical effectiveness of ChEIs for AD remains a subject of contrasting opinions and ongoing debate.

Observation:

Clinical trials present divergent conclusions on ChEI efficacy, with some questioning cost-effectiveness and others affirming benefits for mild to moderate AD.
Current evidence suggests that established ChEIs like donepezil, rivastigmine, and galantamine primarily act through cholinesterase inhibition.
No significant pharmacological actions beyond cholinesterase inhibition have been identified for these classical ChEIs that contribute to therapeutic efficacy.

Findings:

The clinical efficacy of cholinesterase inhibitors (ChEIs) in treating Alzheimer Disease (AD) is a subject of ongoing debate.
Established ChEIs demonstrate efficacy in improving cognitive function in mild to moderate AD, irrespective of their specific enzyme inhibition profile.
Current evidence indicates that the therapeutic benefits of classical ChEIs are primarily attributed to their cholinesterase inhibition activity.

Implications:

The development of novel, multifunctional ChEIs represents the future direction for cholinergic therapy in AD.
Further research into ChEIs may expand their therapeutic applications to conditions such as vascular dementia and mild cognitive impairment.
The potential for ChEIs to enhance memory and learning in healthy individuals raises ethical considerations for future applications.